Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder: Twenty-four-week placebo-controlled dose-ranging study
Open accessAbstract
Background: Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment. Aims: To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD. Method: A total of 541 out-patients, 18–86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER. Results: All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups. Conclusions: Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Case reports of new withdrawal symptoms (hypomania, anxiety, restless sleep, nightmares, depersonalization, formication, headache) after discontinuation of trazodone were published.
“Case reports of new withdrawal symptoms (i.e., hypomania, anxiety, restless sleep, nightmares, depersonalization, formication, headache) after discontinuation of trazodone were published [98-101].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [101]
The Study rationale mentions trazodone only as a treatment for generalised anxiety disorder. The Adverse events section describes discontinuation symptoms after venlafaxine ER, not trazodone. A search for trazodone withdrawal case reports and the listed symptoms found no passage addressing the claim; page numbers were unavailable in our copy. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,841 · see citing works
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139 · see citing works
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455 · see citing works
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
Assessment of social adjustment by patient self report.
Weissman, M. M. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770090101010 · Cited by 1,782 · see citing works
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967 · see citing works
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574 · see citing works
Antidepressants for the Treatment of Generalized Anxiety Disorder
Rickels, K. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820230054005 · Cited by 412 · see citing works
Goa, K. L., & Ward, A. (1986) · Drugs · doi:10.2165/00003495-198632020-00002 · Cited by 334 · see citing works
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332 · see citing works
Merikangas, K. R., Angst, J., Eaton, W., Canino, G., Rubio-Stipec, M., Wacker, H., Wittchen, H.-U., Andrade, L., Essau, C., Whitaker, A., et al. (1996) · British Journal of Psychiatry · doi:10.1192/s0007125000298425 · Cited by 293 · see citing works
Fisher, P., & Durham, R. C. (1999) · Psychological Medicine · doi:10.1017/s0033291799001336 · Cited by 277 · see citing works
The brief scale for anxiety: a subdivision of the comprehensive psychopathological rating scale.
Tyrer, P. J., Owen, R. T., & Cicchetti, D. (1984) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.47.9.970 · Cited by 273 · see citing works
Judd, L. L., Kessler, R. C., PauIus, M. P., Zeller, P. V., Wittchen, H. ‐., & Kunovac, J. L. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb05960.x · Cited by 222 · see citing works
Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors
Zohar, J., & Westenberg, H. G. M. (2000) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2000.tb10947.x · Cited by 218 · see citing works
The benzodiazepine withdrawal symptom questionnaire
Tyrer, P., Murphy, S., & Riley, P. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90009-w · Cited by 188 · see citing works
Modigh, K., Westberg, P., & Eriksson, E. (1992) · PubMed · Cited by 100 · see citing works
Superiority of Clomipramine over Imipramine in the
Modigh, K., Westberg, P., & Eriksson, E. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199208000-00007 · Cited by 92 · see citing works
Resistance to the Anti-Anxiety Effect of Buspirone in Patients with a History of Benzodiazepine Use
Schweizer, E. E., Rickels, K., & Lucki, I. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603133141121 · Cited by 83 · see citing works
Bitsios, P., Szabadi, E., & Bradshaw, C. M. (1999) · Psychopharmacology · doi:10.1007/s002130050949 · Cited by 73 · see citing works
Abdelmawla, Langley, Szabadi, & Bradshaw (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00031.x · Cited by 58 · see citing works
Lorazepam—Efficacy, side effects, and rebound phenomena
Scharf, M. B., & Jacoby, J. A. (1982) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1982.27 · Cited by 43 · see citing works
Melichar, J., Haida, A., Rhodes, C. J., Reynolds, A. H., Nutt, D., & Malizia, A. L. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500102 · Cited by 28 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090 · see citing works
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 963 · see citing works
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H., & WFSBP Task Force on Treatment Guide (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 862 · see citing works
Generalized anxiety disorder: prevalence, burden, and cost to society
Wittchen, H.-U. (2002) · Depression and Anxiety · doi:10.1002/da.10065 · Cited by 733 · see citing works
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617 · see citing works
Stahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 462 · see citing works
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265 · see citing works
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243 · see citing works
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209 · see citing works
Rynn, M. A., Riddle, M. A., Yeung, P. P., & Kunz, N. R. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.2.290 · Cited by 185 · see citing works
An effect-size analysis of pharmacologic treatments for generalized anxiety disorder
Hidalgo, R. B., Tupler, L. A., & Davidson, J. R. T. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107076996 · Cited by 178 · see citing works
Evidence-based pharmacological treatment of generalized anxiety disorder
Baldwin, D. S., Waldman, S., & Allgulander, C. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001434 · Cited by 174 · see citing works
Self-citationEfficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder
Pohl, R. B., Feltner, D. E., Fieve, R. R., & Pande, A. C. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000155820.74832.b0 · Cited by 167 · see citing works
Bandelow, B., Zohar, J., Hollander, E., Kasper, S. F., Möller, H., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150621 · Cited by 167 · see citing works
Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder
Hoehn‐Saric, R., Schlund, M. W., & Wong, S. H. (2004) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2004.02.003 · Cited by 163 · see citing works
Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder
Liebowitz, M. R., Gelenberg, A. J., & Munjack, D. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.190 · Cited by 163 · see citing works
Antidepressants for generalised anxiety disorder (GAD)
Kapczinski, F. P., Souza, J. J. D. S., da Cunha, A. A. B. M., & Schmitt, R. R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003592 · Cited by 163 · see citing works
RetractedHeuzenroeder, L., Donnelly, M., Haby, M. M., Mihalopoulos, C., Rossell, R., Carter, R., Andrews, G., & Vos, T. (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01423.x · Cited by 161 · see citing works
Davidson, J., Rothbaum, B. O., Tucker, P., Asnis, G., Benattia, I., & Musgnung, J. J. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000222514.71390.c1 · Cited by 157 · see citing works
Carl, E., Witcraft, S. M., Kauffman, B. Y., Gillespie, E. M., Becker, E. S., Cuijpers, P., Van Ameringen, M., Smits, J. A. J., & Powers, M. B. (2020) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2018.1560358 · Cited by 151 · see citing works
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149 · see citing works
Boerner, R. J., Sommer, H., Berger, W. L., Kühn, U., Schmidt, U., & Mannel, M. (2003) · Phytomedicine · doi:10.1078/1433-187x-00309 · Cited by 141 · see citing works
Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder
Allgulander, C., Dahl, A. A., Austin, C., Morris, P., Søgaard, J., Fayyad, R. S., Kutcher, S., & Clary, C. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1642 · Cited by 139 · see citing works
Self-citationA Meta-analytic Review of the Efficacy of Drug Treatment in Generalized Anxiety Disorder
Mitte, K., Noack, P., Steil, R., & Hautzinger, M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000155821.74832.f9 · Cited by 137 · see citing works
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131 · see citing works
Prevention of relapse in generalized anxiety disorder by escitalopram treatment
Allgulander, C., Florea, I., & Huusom, A. K. T. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005973 · Cited by 130 · see citing works
Self-citationLong-term efficacy of pregabalin in generalized anxiety disorder
Feltner, D. E., Wïttchen, H., Kavoussi, R. J., Brock, J., Baldinetti, F., & Pande, A. C. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f0f0d7 · Cited by 126 · see citing works
Evidence-based pharmacotherapy of Generalized Anxiety Disorder
Baldwin, D. S., & Polkinghorn, C. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004870 · Cited by 126 · see citing works
Gomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125 · see citing works
Generalized anxiety disorder: comorbidity, comparative biology and treatment
Nutt, D., Ballenger, J. C., Sheehan, D. V., & Wïttchen, H. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003048 · Cited by 122 · see citing works
Advances in the treatment of depression
Holtzheimer, P. E., & Nemeroff, C. B. (2006) · NeuroRx · doi:10.1016/j.nurx.2005.12.007 · Cited by 117 · see citing works
Allgulander, C., Mangano, R. M., Zhang, J., Dahl, A. A., Lepola, U. M., Sjödin, I., & Emilien, G. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.602 · Cited by 113 · see citing works
Self-citationStein, M. B., Pollack, M. H., Bystritsky, A., Kelsey, J. E., & Mangano, R. M. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1957-9 · Cited by 110 · see citing works
Pollack, M. H., Lepola, U. M., Koponen, H., Simon, N. M., Worthington, J. J., Emilien, G., Tzanis, E. L., Salinas, E. O., Whitaker, T., & Gao, B. (2006) · Depression and Anxiety · doi:10.1002/da.20218 · Cited by 104 · see citing works
Self-citationGutierrez, M. A., Stimmel, G. L., & Aiso, J. Y. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80210-2 · Cited by 100 · see citing works
Structural and functional neuroimaging studies in generalized anxiety disorder: a systematic review
Madonna, D., Delvecchio, G., Soares, J. C., & Brambilla, P. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2018-0108 · Cited by 99 · see citing works
Rickels, K., Mangano, R. M., & Khan, A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000138764.31106.60 · Cited by 98 · see citing works
Kasper, S. F., Herman, B. K., Nivoli, G., Ameringen, M. V., Petralia, A., Mandel, F. S., Baldinetti, F., & Bandelow, B. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32831d7980 · Cited by 95 · see citing works
Dell’Osso, B. M., Buoli, M., Baldwin, D. S., & Altamura, A. C. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1074 · Cited by 94 · see citing works
Ciraulo, D. A., Barlow, D. H., Gulliver, S. B., Farchione, T. J., Morissette, S. B., Kamholz, B. W., Eisenmenger, K., Brown, B., Devine, E. G., Brown, T. A., et al. (2013) · Behaviour Research and Therapy · doi:10.1016/j.brat.2013.08.003 · Cited by 92 · see citing works
WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder
Allgulander, C., Bandelow, B., Hollander, E., Montgomery, S., Nutt, D., Okasha, A., Pollack, M. H., Stein, D. J., & Swinson, R. P. (2003) · CNS Spectrums · doi:10.1017/s1092852900006945 · Cited by 92 · see citing works
Self-citationPregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention
Bandelow, B., Wedekind, D., & León, T. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.7.769 · Cited by 85 · see citing works
The Diagnosis and Treatment of Generalized Anxiety Disorder
Bandelow, B., Boerner, R. J., Kasper, S. F., Linden, M., Wïttchen, H., & Möller, H. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0300 · Cited by 82 · see citing works
Overuse of Antidepressant Drugs for the Treatment of Depression
Jureidini, J. N., & Tonkin, A. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00002 · Cited by 81 · see citing works
Maneeton, N., Maneeton, B., Woottiluk, P., Likhitsathian, S., Suttajit, S., Boonyanaruthee, V., & Srisurapanont, M. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s89485 · Cited by 80 · see citing works
Baldomero, E. B., Ubago, J. G., Cercós, C. L., Ruiloba, J. V., Calvo, C. G., Lopez, R., & for the ARGOS Study Group (2005) · Depression and Anxiety · doi:10.1002/da.20080 · Cited by 75 · see citing works
Generalized Anxiety Disorder: Acute and Chronic Treatment
Rynn, M. A., & Brawman‐Mintzer, O. (2004) · CNS Spectrums · doi:10.1017/s1092852900022367 · Cited by 75 · see citing works
Pollack, M. H., Mangano, R. M., Entsuah, R., Tzanis, E. L., & Simon, N. M. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0821-0 · Cited by 73 · see citing works
Bidzan, L., Mahableshwarkar, A. R., Jacobsen, P. L., Yan, M., & Sheehan, D. V. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.012 · Cited by 72 · see citing works
Venlafaxine Versus Placebo in the Preventive Treatment of Recurrent Major Depression
Montgomery, S., Entsuah, R., Hackett, D., Kunz, N. R., Rudolph, R. L., & Venlafaxine 335 Study Group (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0307 · Cited by 69 · see citing works
Self-citationMontgomery, S., Sheehan, D. V., Meoni, P., Haudiquet, V., & Hackett, D. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00005-5 · Cited by 68 · see citing works
Self-citationThe pharmacological management of childhood anxiety disorders: a review
Reinblatt, S. P., & Riddle, M. A. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0644-4 · Cited by 67 · see citing works
Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)
Davidson, J., Zhang, W., Connor, K., Ji, J., Jobson, K. O., Lecrubier, Y., McFARLANE, A. C., Newport, D. J., Nutt, D., Osser, D. N., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108096505 · Cited by 63 · see citing works
Anxiety disorders in older adults
Lauderdale, S. A., & Sheikh, J. I. (2003) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(03)00047-8 · Cited by 61 · see citing works
Physician Withdrawal Checklist (PWC-20)
Rickels, K., Garcia-Espana, F., Mandos, L. A., & Case, G. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817efbac · Cited by 59 · see citing works
Anxiety Symptoms and Generalized Anxiety Disorder in the Elderly: A Review
Alwahhabi, F. (2003) · Harvard Review of Psychiatry · doi:10.1080/10673220303944 · Cited by 59 · see citing works
Lenox‐Smith, A., & Reynolds, A. (2003) · Europe PMC (PubMed Central) · Cited by 58 · see citing works
Treatment-Resistant Panic Disorder
Bandelow, B., & Rüther, E. (2004) · CNS Spectrums · doi:10.1017/s1092852900022379 · Cited by 57 · see citing works
Management of Generalized Anxiety Disorder in Primary Care
Davidson, J. R. T., Feltner, D. E., & Dugar, A. (2010) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.09r00772blu · Cited by 55 · see citing works
Steiner, M. S., Allgulander, C., Ravindran, A. V., Kosar, H., Burt, T., & Austin, C. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.648 · Cited by 55 · see citing works
Self-citationBose, A., Korotzer, A. R., Gommoll, C., & Li, D. (2007) · Depression and Anxiety · doi:10.1002/da.20355 · Cited by 53 · see citing works
A Review of the Diagnosis, Pharmacologic Treatment, and Economic Aspects of Anxiety Disorders
Arikian, S. R., & Gorman, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0302 · Cited by 53 · see citing works
Defining Response and Remission in Anxiety Disorders: Toward an Integrated Approach
Bandelow, B. (2006) · CNS Spectrums · doi:10.1017/s1092852900025815 · Cited by 52 · see citing works
Generalized anxiety disorder publications: Where do we stand a decade later?
Dugas, M. J., Anderson, K. G., Deschênes, S. S., & Donegan, E. (2010) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2010.05.012 · Cited by 50 · see citing works
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49 · see citing works
Schmitt, R. L. D. S., Gazalle, F. K., de Lima, M. S., Cunha, A. B. M., Souza, J. S., & Kapczinski, F. P. (2005) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462005000100007 · Cited by 48 · see citing works
Alaka, K., Noble, W. C., Montejo, A. L., Dueñas, H., Munshi, A., Strawn, J. R., Lenox‐Smith, A., AHL, J. S. B., Bidzan, L., Dorn, B., et al. (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4088 · Cited by 47 · see citing works
Nimatoudis, I., Zissis, N. P., Kogeorgos, J., Theodoropoulou, S., Vidalis, A. A., & KAPRINIS, G. S. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200411000-00003 · Cited by 47 · see citing works
Hackett, D., Haudiquet, V., & Salinas, E. O. (2003) · European Psychiatry · doi:10.1016/s0924-9338(03)00046-4 · Cited by 47 · see citing works
Self-citationPharmacological Treatments for Worry: Focus on Generalised Anxiety Disorder
Anderson, I. M., & Palm, M. E. (2006) · Wiley eBooks · doi:10.1002/9780470713143.ch18 · Cited by 45 · see citing works
Gommoll, C., Durgam, S., Mathews, M., Forero, G., Núñez, R., Tang, X., & Thase, M. E. (2015) · Depression and Anxiety · doi:10.1002/da.22365 · Cited by 44 · see citing works
Escitalopram in the treatment of generalized anxiety disorder
Baldwin, D. S., & Nair, R. V. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.4.443 · Cited by 42 · see citing works
Stein, D. J., Pedersen, R., ROTHBAUM, B. O., Baldwin, D. S., Ahmed, S., Musgnung, J. J., & Davidson, J. R. T. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008961 · Cited by 41 · see citing works
Bailey, J., Dawson, G. R., Dourish, C. T., & Nutt, D. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111408455 · Cited by 41 · see citing works
Mainio, A., Hakko, H. H., Niemelä, A., Koivukangas, J. P., & Räsänen, P. K. (2011) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2011.05.006 · Cited by 40 · see citing works
Incidence and Nature of Antidepressant Discontinuation Symptoms
Kalfas, M., Tsapekos, D., Butler, M., McCutcheon, R. A., Pillinger, T., Strawbridge, R., Bhat, B. B., Haddad, P. M., Cowen, P. J., Howes, O. D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1362 · Cited by 42 · see citing works
Pharmacological Treatment of Generalized Anxiety Disorder
Baldwin, D. S., Ajel, K. I., & Garner, M. J. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_2 · Cited by 39 · see citing works
Dahl, A. A., Ravindran, A. V., Allgulander, C., Kutcher, S., Austin, C., & Burt, T. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00529.x · Cited by 39 · see citing works
Self-citationPollack, M. H., Meoni, P., Otto, M. W., & Hackett, D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084025.22282.84 · Cited by 38 · see citing works
Self-citationMontgomery, S., Emir, B., Haswell, H., & Prieto, R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.820694 · Cited by 36 · see citing works
Treatment of anxiety disorders with venlafaxine XR
Thase, M. E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.3.269 · Cited by 36 · see citing works
Nash, J. R., & Nutt, D. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-28082-0_17 · Cited by 32 · see citing works
Long-term goals in the management of acute and chronic anxiety disorders.
Kjernisted, K. D., & Bleau, P. (2004) · PubMed · Cited by 29 · see citing works
Bereza, B. G., Machado, M., Ravindran, A. V., & Einarson, T. R. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700805 · Cited by 29 · see citing works
Nutt, D., Allgulander, C., Lecrubier, Y., Peters, T., & Wïttchen, H. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108091068 · Cited by 28 · see citing works
Self-citationEmerging treatments for depression
Holtzheimer, P. E., & Nemeroff, C. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.17.2323 · Cited by 27 · see citing works
Qualitative review of SNRIs in anxiety.
Silverstone, P. H. (2004) · PubMed · Cited by 26 · see citing works
Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER
Tamagnan, G. D., Brenner, E., Alagille, D., Staley, J. K., Haile, C. N., Koren, A. O., Early, M., Baldwin, R. M., Tarazi, F. I., Baldessarini, R. J., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.10.018 · Cited by 25 · see citing works
Duloxetine in the treatment of generalized anxiety disorder
Kornstein, S. G., Russell, J. M., Spann, M. E., Crits-Christoph, P. F., & Ball, S. G. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.9.2.155 · Cited by 25 · see citing works
Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders
Baldwin, D. S. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600637056 · Cited by 25 · see citing works
Venlafaxine versus Mirtazapine in the??Treatment of Undifferentiated Somatoform Disorder
Han, C., Pae, C.-U., Lee, B. H., Ko, Y., Masand, P. S., Patkar, A. A., Joe, S., & Jung, I. K. (2008) · Clinical Drug Investigation · doi:10.2165/00044011-200828040-00006 · Cited by 24 · see citing works
Long term therapy of generalized anxiety disorder
Rouillon, F. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.01.001 · Cited by 24 · see citing works
Meta-analysis: Risk of hyperhidrosis with second-generation antidepressants
Beyer, C., Cappetta, K., Johnson, J. A., & Bloch, M. H. (2017) · Depression and Anxiety · doi:10.1002/da.22680 · Cited by 23 · see citing works
Treatments for generalized anxiety disorder
Struzik, L., Vermani, M., Coonerty-Femiano, A., & Katzman, M. A. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.2.285 · Cited by 23 · see citing works
Stahl, S. M., Ahmed, S., & Haudiquet, V. (2007) · CNS Spectrums · doi:10.1017/s1092852900021544 · Cited by 21 · see citing works
Perugi, G., Frare, F., Toni, C., Ruffolo, G., & Torti, C. (2002) · Neuropsychobiology · doi:10.1159/000066391 · Cited by 21 · see citing works
Montgomery, S., Mahé, V., Haudiquet, V., & Hackett, D. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200212000-00005 · Cited by 21 · see citing works
Self-citationThe Neurotherapy of Anxiety Disorders
Moore, N. C. (2005) · Journal of Adult Development · doi:10.1007/s10804-005-7031-y · Cited by 20 · see citing works
Therapeutic Implications of microRNAs in Depressive Disorders: A Review
Hassan, M., Amir, A., Shahzadi, S., & Kloczkowski, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113530 · Cited by 19 · see citing works
Venlafaxine in the treatment of anxiety disorders
Katzman, M. A. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.3.371 · Cited by 18 · see citing works
- Authors
- Allgulander, C., Hackett, D., & Salinas, E.
- Corresponding author
- Allgulander, Christer
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2001-07
- Volume
- 179
- Issue
- 1
- Pages
- 15-22
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2122087038
- Cited by
- 175
- References
- 23
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 2 · 2014: 3 · 2013: 7 · 2012: 5
- FWCI
- 25.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The British Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Karolinska Institutet
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- venlafaxine extended release, generalized anxiety disorder, antidepressant efficacy, drug safety, long-term treatment, dose comparison, treatment discontinuation
- MeSH terms
- Venlafaxine Hydrochloride, Adolescent, Adult, Aged, Aged, 80 and over, Anxiety Disorders, Chronic Disease, Cyclohexanols, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
